Top

Osteoporosis International

Published in:

01-01-2016 | Original Article

The use of bisphosphonate in the treatment of osteonecrosis of the femoral head: a meta-analysis of randomized control trials

Authors: H.-f. Yuan, C.-a. Guo, Z.-q. Yan

Published in: Osteoporosis International | Issue 1/2016

Abstract

Summary

This meta-analysis revealed that bisphosphonates could not provide a better clinical outcome in the treatment of osteonecrosis of the femoral head (ONFH) when compared with placebo.

Introduction

Bisphosphonates have been recommended to treat ONFH. However, the exact clinical outcomes after treatment are still controversial.

Methods

A comprehensive search of PubMed, Embase, and Web of Science databases was undertaken, and only randomized control trials were included. The clinical outcomes consisted of progression to collapse, total hip arthroplasty (THA) incidence, and improvement of Harris hip score (HHS). The heterogeneities between the trials were assessed with the I ² statistic, and random effects models were used for the meta-analysis.

Results

Five eligible trials were identified involving 329 subjects with 920.9 patient-years of follow-up. The clinical outcomes of patients with ONFH was not significantly improved by bisphosphonate therapy (progression to collapse: risk ratio = 0.71 (0.41, 1.24), p = 0.23; THA incidence: risk ratio = 0.61 (0.33, 1.15), p = 0.13; HHS improvement: mean difference = 3.26 (−5.12, 11.64), p = 0.45). The I ² statistic showed the existence of considerable heterogeneity (all I ² ≥ 50 %), which was explained by one trial where bisphosphonate alone was used with no additional therapy. However, when this trial was excluded, the clinical outcomes after bisphosphonate therapy were still not significantly improved compared with placebo.

Conclusions

The current analysis does not support the use of bisphosphonates for ONFH. As potential serious adverse effects are associated with these drugs, only limited use can be recommended.

Herndon JH, Aufranc OE (1972) Avascular necrosis of the femoral head in the adult. A review of its incidence in a variety of conditions. Clin Orthop Relat Res 86:43–62PubMedCrossRef

Mankin HJ (1992) Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 326(22):1473–9PubMedCrossRef

Chang CC, Greenspan A, Gershwin ME (1993) Osteonecrosis: current perspectives on pathogenesis and treatment. Semin Arthritis Rheum 23(1):47–69PubMedCrossRef

Jergesen HE, Khan AS (1997) The natural history of untreated asymptomatic hips in patients who have non-traumatic osteonecrosis. J Bone Joint Surg Am 79:359–63PubMed

Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Alendronate Phase III Osteoporosis Treatment Study Group (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–99PubMedCrossRef

Silverman S, Christiansen C (2012) Individualizing osteoporosis therapy. Osteoporos Int 23(3):797–809PubMedCrossRef

Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15(11):862–71PubMedCrossRef

Little DG, Peat RA, Mcevoy A, Williams PR, Smith EJ et al (2003) Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J Bone Miner Res 18:2016–22PubMedCrossRef

Hofstaetter JG, Wang J, Yan J, Glimcher MJ (2006) Changes in bone microarchitecture and bone mineral density following experimental osteonecrosis of the hip in rabbits. Cells Tissues Organs 184:138–47PubMedCrossRef

10.

Hofstaetter JG, Wang J, Yan J, Glimcher MJ (2009) The effects of alendronate in the treatment of experimental osteonecrosis of the hip in adult rabbits. Osteoarthritis Cartilage 17:362–70PubMedCrossRef

11.

Agarwala S, Jain D, Joshi VR, Sule A (2005) Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford) 44(3):352–9CrossRef

12.

Agarwala S, Shah S, Joshi VR (2009) The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years. J Bone Joint Surg Br 91(8):1013–8PubMedCrossRef

13.

Agarwala S, Shah SB (2011) Ten-year follow-up of avascular necrosis of femoral head treated with alendronate for 3 years. J Arthroplasty 26(7):1128–34PubMedCrossRef

14.

Wang CJ, Wang FS, Yang KD, Huang CC, Lee MS et al (2008) Treatment of osteonecrosis of the hip: comparison of extracorporeal shockwave with shockwave and alendronate. Arch Orthop Trauma Surg 128(9):901–8PubMedCrossRef

15.

Chen CH, Chang JK, Lai KA, Hou SM, Chang CH et al (2012) Alendronate in the prevention of collapse of the femoral head in nontraumatic osteonecrosis: a two-year multicenter, prospective, randomized, double-blind, placebo-controlled study. Arthritis Rheum 64(5):1572–8PubMedCrossRef

16.

Hong YC, Luo RB, Lin T, Zhong HM, Shi JB (2014) Efficacy of alendronate for preventing collapse of femoral head in adult patients with nontraumatic osteonecrosis. Biomed Res Int 2014:716538PubMedPubMedCentral

17.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7), e1000097PubMedPubMedCentralCrossRef

18.

Higgins JPT, Altman DG (2008) Assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 501. Wiley, Chichester, UKCrossRef

19.

Nishii T, Sugano N, Miki H, Hashimoto J, Yoshikawa H (2006) Does alendronate prevent collapse in osteonecrosis of the femoral head? Clin Orthop Relat Res 443:273–9PubMedCrossRef

20.

Ramachandran M, Ward K, Brown RR, Munns CF, Cowell CT et al (2007) Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. J Bone Joint Surg Am 89(8):1727–34PubMedCrossRef

21.

Hsu SL, Wang CJ, Lee MS, Chan YS, Huang CC et al (2010) Cocktail therapy for femoral head necrosis of the hip. Arch Orthop Trauma Surg 130(1):23–9PubMedCrossRef

22.

Kang P, Pei F, Shen B, Zhou Z, Yang J (2012) Are the results of multiple drilling and alendronate for osteonecrosis of the femoral head better than those of multiple drilling? A pilot study. Joint Bone Spine 79(1):67–72PubMedCrossRef

23.

Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT et al (2005) The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am 87(10):2155–9PubMedCrossRef

24.

Lee YK, Ha YC, Cho YJ, Suh KT, Kim SY, Won YY et al (2015) Does zoledronate prevent femoral head collapse from osteonecrosis? A prospective, randomized, open-label, multicenter study. J Bone Joint Surg Am 97(14):1142–8PubMedCrossRef

25.

Jobke B, Milovanovic P, Amling M, Busse B (2014) Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients. Bone 59:37–43PubMedCrossRef

26.

Abe Y, Iba K, Sasaki K, Chiba H, Kanaya K et al (2015) Inhibitory effect of bisphosphonate on osteoclast function contributes to improved skeletal pain in ovariectomized mice. J Bone Miner Metab 33(2):125–34PubMedCrossRef

27.

Abrahamsen B (2010) Adverse effects of bisphosphonates. Calcif Tissue Int 86:421–435PubMedCrossRef

Title: The use of bisphosphonate in the treatment of osteonecrosis of the femoral head: a meta-analysis of randomized control trials
Authors: H.-f. Yuan
C.-a. Guo
Z.-q. Yan
Publication date: 01-01-2016
Publisher: Springer London
Published in: Osteoporosis International / Issue 1/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-015-3317-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The use of bisphosphonate in the treatment of osteonecrosis of the femoral head: a meta-analysis of randomized control trials

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Cost-effectiveness of vitamin D supplementation and exercise in preventing injurious falls among older home-dwelling women: findings from an RCT

Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study

Relationship between subclinical thyroid dysfunction and the risk of fracture: a meta-analysis of prospective cohort studies

Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury

Effect of IV contrast on lumbar trabecular attenuation at routine abdominal CT: correlation with DXA and implications for opportunistic osteoporosis screening

Fracture prediction from repeat BMD measurements in clinical practice